- Abstract
- 10.1136/ijgc-2024-igcs.607
TP005/#1564 Gog-3069: phase 2 study of alpelisib and fulvestrant for PIK3CA-mutated estrogen receptor-positive endometrioid endometrial cancers
- Oct 01, 2024
- International Journal of Gynecologic Cancer
- Stephanie Gaillard + 13 more +13
IntroductionKnowledge of the molecular landscape of endometrial cancer is driving novel treatment development for persistent, metastatic, or recurrent disease. Endocrine-based combinations such as aromatase inhibitors with mTOR or CDK4/6 inhibitors have shown benefit especially in patients not previously treated with chemotherapy. Oncogenic PIK3CA mutations impact response to aromatase inhibitors in breast cancer. Alpelisib + fulvestrant is approved for treatment of metastatic hormone receptor-positive, HER2-negative breast cancer harboring PIK3CA mutations after progression on endocrine therapy. PIK3CA mutations are common in endometrial cancers and may similarly confer endocrine resistance. GOG3069 is a phase II trial evaluating the efficacy and safety of alpelisib + fulvestrant in biomarker-selected endometrial cancer patients.MethodsGOG-3069 is a phase II non-randomized, open-label, multicenter, two-stage study. Eligible patients have advanced (FIGO2014 Stage III/IV), persistent, or recurrent endometrial carcinoma with RECISTv1.1 measurable disease. Patients cannot be curable by surgery or radiotherapy. Other criteria: endometrioid histology with estrogen receptor expression (≥1% of tumor cells) and oncogenic PIK3CA mutation, ≤3 prior lines of therapy including 1 systemic chemotherapy. Enrolled patients will receive alpelisib 300mg orally daily and fulvestrant 500mg IM Cycle 1 Day 1 and Day 15, then 500mg IM on Day 1 of each 28-day cycle. The primary endpoint is overall response rate by RECISTv1.1. Secondary endpoints include safety, tolerability, progression-free survival, duration of response, and 24-month overall survival rate. The statistical plan uses a conditional-stratified design factoring differing probabilities of response based on prior chemotherapy exposure.Current Trial StatusGOG-3069 activated in November 2023 and will enroll across 15 US sites.
Read more